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Abstract. 27 
Background.  Diazabicyclooctanes, e.g. avibactam and relebactam, are a new class of -28 
lactamase inhibitors. Their spectrum includes AmpC enzymes, but it is important to 29 
understand if they also induce these enzymes.  Methods.  Levels of ampC mRNA were 30 
measured by RT-PCR during 4h exposure of Enterobacter cloacae, Citrobacter freundii and 31 
Pseudomonas aeruginosa (n=5 strains per species) to avibactam, relebactam and cefoxitin 32 
at 0, 1, 4 and 32 mg/L.  The method had low precision compared with conventional specific-33 
activity-based induction assays, which are impracticable for inhibitors. Accordingly, induction 34 
was only considered to be significant if induction ratios >10-fold were found at two 35 
consecutive time intervals, with ‘strong induction’ if one of more ratio was >100. Results. 36 
Cefoxitin, as expected, gave concentration-dependent induction for all strains, with strong 37 
induction for 13/15.  At the other extreme, relebactam caused no significant induction for any 38 
strain.  Avibactam gave strain-variable results, with strong concentration-dependent induction 39 
for 2/5 E. cloacae and 2/5 P. aeruginosa but little or no induction for the other strains, 40 
including all the C. freundii. Conclusions. Avibactam, but not relebactam, had some strain-41 
variable ability to induce AmpC enzymes though at concentrations (32 mg/L) above those 42 
reached in the patient. 43 
44 
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Introduction 45 
Diazabicyclooctanes (DBOs) such as avibactam and relebactam inhibit AmpC -lactamases .  46 
1,2  It is of interest to know if they also induce these enzymes, both to answer the question of 47 
whether a non--lactam can induce and because induction hypothetically might lead to 48 
antagonism if the DBO is combined with a weak-inducer -lactam and the AmpC enzyme had 49 
mutated so as to become resistant to inhibition by DBOs.  On this basis we examined the 50 
AmpC inducer behaviour of avibactam and relebactam for Enterobacter cloacae, Citrobacter 51 
freundii and Pseudomonas aeruginosa, as the species where these enzymes are most 52 
important.    53 
 Because it is impracticable to measure -lactamase specific activity when an inducer 54 
is also an inhibitor, we adopted an alternative approach, using RT-PCR to measure the levels 55 
of AmpC-encoding mRNA.  56 
 57 
Materials and Methods 58 
Organisms 59 
The test strains were reference submissions to PHE, collected in 2010-11, or were from an 60 
earlier UK survey.3 They comprised five isolates each of E. cloacae, C. freundii and P. 61 
aeruginosa.  The E. cloacae and C. freundii strains were confirmed as AmpC inducible, 62 
based on being susceptible (MICs <1 mg/L) to cefotaxime and ceftazidime but resistant to 63 
cefoxitin, with antagonism of cefotaxime and ceftazidime by cefoxitin in double disc tests;4 P. 64 
aeruginosa isolates were AmpC inducible based on being susceptible to carbenicillin (MIC 65 
<128 mg/L) and ceftazidime (MIC <2 mg/L), with antagonism of ceftazidime by imipenem in 66 
double disc tests.  All the strains were susceptible to imipenem at CLSI breakpoints; MICs of 67 
avibactam and relebactam ranged from 16->128 mg/L.   68 
 69 
Antibiotics 70 
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Avibactam and ceftaroline were provided by AstraZeneca (Wilmington, Delaware, USA); 71 
imipenem and relebactam were supplied by Merck Sharp & Dohme Corp. (Whitehouse 72 
Station, NJ, USA); ceftazidime and cefoxitin was purchased from Sigma (Poole, Dorset, UK). 73 
 74 
Susceptibility tests 75 
MICs were determined by CLSI agar dilution.5 76 
 77 
Induction assays 78 
Isolates were grown overnight in 10-mL volumes of LB broth, with 1-mL amounts of these 79 
cultures then used to inoculate 100-mL volumes of fresh LB.  The diluted cultures were 80 
incubated with shaking to OD600 of 0.4-0.5, then inducers (cefoxitin, avibactam or relebactam) 81 
were added at 0, 1, 4 or 32 mg/L. Cultures were sampled immediately before this addition 82 
and at 30, 60, 120 and 240 minutes thereafter, with 0.5 mL samples transferred to 2-mL 83 
tubes containing 1 mL of RNAprotect (Qiagen, Manchester UK). These samples were mixed, 84 
centrifuged at 13000 rpm for 10 min, with the pellets retained at -80C pending RNA 85 
extraction. 86 
 87 
RNA extraction 88 
Cellular RNA was extracted with an RNA Purification 96-Well Kit (Norgen, Thorold, Canada), 89 
used according to manufacturer’s instructions. Briefly, the bacterial pellet was resuspended in 90 
75 µL of TE buffer containing 1 mg/mL lysozyme and incubated at room temperature for 5 91 
min. Afterwards, 225 µL of Lysis Solution was added followed, after mixing, by 120 µL of 95-92 
100% ethanol. The resulting lysate was transferred to a 96-well filter plate and the RNA 93 
binding, wash, and elution steps were followed. On-filter genomic DNA digestion was 94 
performed using the RNase-free DNase I Kit (Norgen), used in accordance with the 95 
manufacturer’s instructions.  96 
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 97 
RT-PCR assay.         98 
Primers (Sigma) and probes (Applied Biosystems, Life Technologies, Paisley, UK) were as 99 
detailed in Table 1. Probes were labelled with either 6-FAM (6-carboxy-fluorescein) or VIC® 100 
at the 5' end, and with TAMRA (6-carboxy-tetramethyl-rhodamine) at the 3' end.  RT-PCR 101 
was performed using the TaqMan RNA-to-CT 1-Step kit (Applied Biosystems). Each reaction 102 
was prepared in a 20-µL volume and contained: 1 x TaqMan RT-PCR mix, 0.5 µL of RT 103 
enzyme mix, 500 nM of each primer, 250 nM of each probe and 1 µL of RNA template. The 104 
RT-PCR consisted of a reverse transcription step for 15 min at 48C, followed by an 105 
activation step of 10 min at 95C and 40 cycles of denaturation for 15 sec at 95C and 106 
anneal/extension for 1 min at 60C. The absence of genomic DNA contamination was verified 107 
for each RNA preparation by running RT-PCR without reverse transcriptase. The reactions 108 
and data analyses were conducted using the Fast Real-Time PCR System 7500 (Applied 109 
Biosystems).  Reactions were performed in triplicate.  cDNA derived from expression of 110 
ampC was measured relative to that arising from housekeeping genes, namely guaA in P. 111 
aeruginosa, rpoB in C. freundii and rspL in E. cloacae, thereby correcting for differences in 112 
the amount of starting material.  These standardised estimates of ampC transcript-derived 113 
cDNA were then re-standardised against ampC transcript-derived cDNA in the non-induced 114 
culture at the same time point. Relative quantification was carried out by using the 2-∆∆Ct 115 
method, where the Ct value is defined as the first PCR cycle at which the fluorescence is 116 
above the threshold value of 0.2, as recommended by the thermal cycler instrument 117 
manufacturer.6 An induction ratio was thus defined as: (time t ampC signal ÷ time t 118 
housekeeping signal) / (time 0 ampC signal ÷ time 0 housekeeping signal), with results 119 
averaged across the three replicate mixtures. 120 
 121 
 122 
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Results and Discussion 123 
Susceptibility 124 
The test strains – which were confirmed as AmpC-inducible – all were susceptible to ceftazidime 125 
and imipenem in the absence of DBOs (Table 2). C. freundii H121940571 was narrowly resistant 126 
to ceftaroline (MIC 1 mg/L versus a breakpoint of 0.5 mg/L); all the P. aeruginosa strains tested 127 
(5/5) also had inherent resistance to ceftaroline, as is typical of the species.  Addition of DBOs 128 
caused small reductions in the MICs of the partner -lactams (Table 2), typically 2- to 4- fold.  No 129 
antagonism was seen. 130 
 131 
Induction assays   132 
RT-PCR-based induction assays (Table 3) proved less precise than those based on 133 
measurement of -lactamase specific activity (see e.g. ref 7), no doubt owing to the much more 134 
complex multi-step method needed for estimation, and perhaps also because mRNA persists 135 
more briefly than induced AmpC enzyme. This variability is reflected in the scatter of induction 136 
ratios, from 0.1-58, for the T0 estimates, where values around unity would be expected.  137 
Moreover, assays for avibactam and relebactam were run several months apart, each time with 138 
cefoxitin as a control, and, whilst both sets of experiments showed that cefoxitin induced 139 
strongly, there was considerable inter-run scatter for results with this cephamycin, without clear 140 
systematic bias (not shown).  On this basis we only considered induction significant if induction 141 
ratios >10 were obtained for at least two successive time points, whilst ‘Strong’ induction was 142 
taken as one ratio >100, with a ratio >10 at the preceding or subsequent time point.  Based upon 143 
these criteria, cefoxitin counted as an inducer for all 15 strains and a strong inducer for all except 144 
one C. freundii and one P. aeruginosa. The rises in AmpC mRNA were greatest and most 145 
prolonged at the highest cefoxitin concentration (32 mg/L), but induction was often also apparent 146 
with the drug at 4 mg/L, confirming a dose-response relationship. These data are in keeping with 147 
a considerable body of data from conventional induction assays.7 148 
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 Relebactam, at the other extreme, gave no convincing evidence of induction for any 149 
strain, with only two isolated instances of ratios >10, neither of them supported by raised ratios at 150 
adjacent time points nor with any relation to concentration.  Avibactam had more variable 151 
behaviour, meeting our definitions of a strong inducer for 2/5 E. cloacae and 2/5 P. aeruginosa at 152 
highest avibactam concentration (32 mg/L). However there was no significant induction for the 153 
other 11/15 strains, including all the C. freundii, nor at lower avibactam concentrations. Miossec 154 
et al.8 studied a further three E. cloacae by similar methodology and found no AmpC induction by 155 
avibactam at up to 64 mg/L.  156 
 Strain-to-strain differences in inducer response to avibactam may be a thresholding 157 
effect, with the top concentration tested being on the border of that needed for induction, whilst 158 
the differences in inducer power between avibactam and relebactam may reflect difference in the 159 
strength of PBP interactions.  By itself avibactam has greater activity and lower MICs than 160 
relebactam, albeit with values significantly above the clinical range, and has been shown by 161 
several researchers to bind to PBP2 of Enterobacteriaceae.9-11   One group also found binding to 162 
PBP4.10  Linking these observations to inducer power is however speculative.  The higher MICs 163 
of relebactam may relate to uptake rather than PBP affinity; moreover the precise links between 164 
PBP inhibition and the perturbation of the peptidoglycan fragment recycling that regulates AmpC 165 
induction12 remain elusive, perhaps because PBP assays only detect the formation of covalent 166 
adducts, not other interactions.  Clavulanic acid, which likewise binds PBP213 is an inducer for 167 
some strains,14 but mecillinam, which also binds this target, has little inducer power.15  PBP4 168 
interactions, as found for avibactam by one group10 have been suggested to be a correlate of 169 
AmpC induction in P. aeruginosa.16   170 
 Any practical significance of AmpC induction by avibactam is doubtful.  Significant 171 
induction with avibactam, where it occurred, was only seen with 32 mg/L avibactam, a 172 
concentration around the Cmax following a standard 500 mg dosage and therefore far above the 173 
mean inter-dose level.17,18,19  Moreover induced enzyme should be inhibited, and ceftazidime-174 
avibactam is active against strains with derepressed AmpC, producing more enzyme than is ever 175 
 8 
 
likely to be induced.1,2  The only circumstances in which this induction might become clinically 176 
significant would be if the AmpC enzyme (i) mutated to lose affinity for avibactam and (ii) 177 
remained inducible. Avibactam-induced enzyme might then attack its partner cephalosporin.  178 
Protein sequence changes within AmpC, arising via mutation, can engender resistance to 179 
ceftaroline/avibactam and ceftazidime/avibactam20 (also PHE, data on file), however these seem 180 
more likely to be selected, if at all, once the enzyme expression is already derepressed, not 181 
when it remains inducible.   We therefore consider the present data largely of academic interest, 182 
in showing that a non-β-lactam can act as an AmpC inducer as well as inhibiting -lactamases 183 
and targeting PBP2. 184 
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Table 1. Primers and probes used in RT-PCR  265 
 266 
Species Primer/probe Sequence (5’ – 3’) 
P. aeruginosa pse_guaA_F CTGACCTGCGTGTTCGTC 
pse_guaA_R GAACATGGCCATCACCTG 
pse_ampC_F ATGAAGGCCAATGACATTCC 
pse_ampC_R CCATAGCTGAAGTAATGCGG 
pse_guaA VIC-CTGCTGCGCCTGCACGAAG-TAMRA 
pse_ampC 6-FAM-TCTCCTTTCAGGCTGATGGCTACGG-TAMRA 
E. cloacae ent_rspL_F ACGTACAGCACCACGACG 
ent_rspL_R AGCGTGTCTTCCAGACTCAC 
ent_ampC_F CGGATGAGGTCACGGATAAC 
ent_ampC_R TGGCGTTGGCGTAAAGA 
ent_rspL VIC-CACTCTCCGGTAGTTGACAGCATTGCT-TAMRA 
ent_ampC 6-FAM-ACTGCGGCTGCCAGTTTTGATAAAAG-TAMRA 
C. freundii cit_rpoB_F CGTACACCCGACTCACTACG 
cit_rpoB_R AGACCGATGTTCGGACCTT 
cit_apmC_F GTGATATGTACCAGGGATTAGGC 
cit_ampC_R AATGCCACTTTGCTGTCG 
cit_rpoB VIC-CGCGTATGTCCAATCGAAACGC-TAMRA 
cit_ampC 6-FAM-ATCGAATCAGCTTTCAGCGGCC-TAMRA 
267 
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Table 2.  MICs (mg/L) for test strains, determined by BSAC agar dilution 268 
 Ceftazidime Ceftaroline Imipenem DBOs alone 
 Alone 
+AVI,  
4 mg/L  
Alone 
+AVI,  
4 mg/L  
Alone 
+REL 
4 mg/L 
AVI REL 
E. cloacae         
H101440920 0.5 0.5 0.5 0.25 0.5 0.125 16 128 
H111900378 0.25 0.25 0.25 0.125 0.5 0.25 32 128 
SE04013 0.5 0.25 0.5 0.5 0.5 0.25 32 128 
SE04027 0.5 0.25 0.25 0.125 0.25 0.125 32 128 
SE06012 0.25 0.25 0.25 0.125 0.5 0.25 32 128 
C. freundii          
H103540377 0.5 0.125 0.5 0.06 0.25 0.125 128 >128 
H121940571 0.5 0.125 1 0.06 0.25 0.25 128 >128 
LN10083 0.5 0.125 0.25 0.06 0.25 NT NT NT 
SE02016 0.5 0.125 0.25 0.06 0.25 0.25 >128 >128 
SE02071 0.5 0.125 0.5 0.12 0.5 0.25 >128 >128 
P. aeruginosa          
H111840682 2 1 8 1 0.25 0.25 >128 >128 
H112220257 2 1 32 8 0.5 0.25 >128 >128 
H114900202 2 2 8 8 2 0.5 >128 >128 
H114980582 2 2 N/T N/T 2 0.25 >128 >128 
H115280631 2 2 16 2 0.5 0.5 >128 >128 
 269 
Cefoxitin MICs were >128 mg/L for all isolates 270 
 271 
Notes to Table 2.  Isolates with numbers starting  LN or SE were collected in a London 272 
and Southeast England survey of resistance in 2004;3 those with numbers starting H10, 273 
H11 and H12 were submissions to PHE's Antimicrobial Resistance and Healthcare 274 
Associated Infection Reference Unit in 2010, 2011 and 2012 respectively. Abbreviations: 275 
AVI, avibactam; NT, not tested; REL, relebactam. 276 
 277 
278 
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Table 3.  AmpC induction ratios for isolates exposed to cefoxitin and DBOs 279 
 280 
Strain Inducer Induction period (minutes) 
  0 30 60 120 240 
E. cloacae H101440920 Cefoxitin 1 mg/L 1.5 50 23 0.85 0.95 
 Cefoxitin 4 mg/L 1.7 2600 2700 8.7 0.75 
 Cefoxitin 32 mg/L 1.6 840 65 25 73 
 Avibactam 1 mg/L 2.3 1.4 0.7 1.1 0.8 
 Avibactam 4 mg/L 1.8 1.1 26 3.5 0.7 
 Avibactam 32 mg/L 1.4 8900 6900 3600 270 
 Relebactam 1 mg/L 1.3 0.8 1.0 0.7 0.9 
 Relebactam 4 mg/L 0.8 0.9 1.4 1.5 0.7 
 Relebactam 32 mg/L 1.2 1.4 1.4 1.5 0.8 
E. cloacae H111900378 Cefoxitin 1 mg/L 1.2 0.85 0.75 1.2 1.1 
 Cefoxitin 4 mg/L 0.35 30 0.8 1.3 0.85 
 Cefoxitin 32 mg/L 0.3 110 35 29 20 
 Avibactam 1 mg/L 0.1 1.6 0.8 1.4 1.2 
 Avibactam 4 mg/L 0.1 4.6 0.6 1.1 1.0 
 Avibactam 32 mg/L 0.1 4600 7400 1.7 1.0 
 Relebactam 1 mg/L 0.5 0.8 1.5 2.1 1.3 
 Relebactam 4 mg/L 0.5 0.8 1.8 2.2 1.5 
 Relebactam 32 mg/L 1.3 1.1 1.6 1.4 1.7 
E. cloacae SE04013 Cefoxitin 1 mg/L 1.3 1.2 1.1 1.4 1.4 
 Cefoxitin 4 mg/L 1.1 67 2.7 1.1 1.0 
 Cefoxitin 32 mg/L 1.3 2900 580 750 1700 
 Avibactam 1 mg/L 0.8 0.7 1.2 0.5 2.1 
 Avibactam 4 mg/L 2.0 1.0 0.6 0.4 2.2 
 Avibactam 32 mg/L 1.3 0.8 0.6 0.4 2.2 
 Relebactam 1 mg/L 2.0 1.7 1.7 1.8 1.2 
 Relebactam 4 mg/L 2.7 1.5 2.2 2.1 1.8 
 Relebactam 32 mg/L 2.6 1.4 2.4 2.1 1.0 
E. cloacae SE04027 Cefoxitin 1 mg/L 1.2 2 0.65 1.05 1 
 Cefoxitin 4 mg/L 1.6 480 1.1 1.4 0.8 
 Cefoxitin 32 mg/L 1.8 4600 420 1300 360 
 Avibactam 1 mg/L 1.2 2.0 1.0 2.8 0.9 
 Avibactam 4 mg/L 1.9 4.6 1.7 1.3 1.2 
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 Avibactam 32 mg/L 2.2 3.8 850 0.9 0.6 
 Relebactam 1 mg/L 1.0 1.2 1.6 1.0 0.9 
 Relebactam 4 mg/L 1.2 1.4 1.3 2.4 1.1 
 Relebactam 32 mg/L 1.4 1.4 1.2 1.9 1.6 
E. cloacae SE06012 Cefoxitin 1 mg/L 0.8 1.2 13 1.1 1.0 
 Cefoxitin 4 mg/L 1.6 26 220 1.8 1.0 
 Cefoxitin 32 mg/L 1.5 1300 250 660 600 
 Avibactam 1 mg/L 0.7 1.4 0.7 1.0 0.4 
 Avibactam 4 mg/L 0.9 1.5 0.7 1.7 0.6 
 Avibactam 32 mg/L 0.6 1.3 0.7 0.8 0.4 
 Relebactam 1 mg/L 2.3 0.6 1.0 0.7 1.1 
 Relebactam 4 mg/L 3.0 0.5 1.7 1.4 1.6 
 Relebactam 32 mg/L 3.9 0.8 1.5 1.2 1.6 
C. freundii H103540377 Cefoxitin 1 mg/L 1.3 11 13 1.7 1.6 
 Cefoxitin 4 mg/L 1.2 100 31 12 4.5 
 Cefoxitin 32 mg/L 1.4a 180 64 89 22 
 Avibactam 1 mg/L 1.3 1.0 0.9 1.3 0.9 
 Avibactam 4 mg/L 1.2 0.6 0.9 1.0 1.0 
 Avibactam 32 mg/L 1.6 0.8 1.3 1.0 0.8 
 Relebactam 1 mg/L (32)b 1.2 0.9 0.6 1.0 
 Relebactam 4 mg/L 1.2 1.2 1.2 0.9 1.2 
 Relebactam 32 mg/L 0.9 1.3 1.2 0.8 0.9 
C. freundii H121940571 Cefoxitin 1 mg/L 0.8 6.3 9.7 5.0 1.1 
 Cefoxitin 4 mg/L 1.0 30 20 42 9.6 
 Cefoxitin 32 mg/L 1.9 75 43 120 41 
 Avibactam 1 mg/L 1.0 1.1 1.3 1.6 3.2 
 Avibactam 4 mg/L 0.5 1.4 0.8 1.6 2.2 
 Avibactam 32 mg/L 1.1 0.8 1.0 0.8 1.1 
 Relebactam 1 mg/L 1.9 0.7 0.7 0.8 1.0 
 Relebactam 4 mg/L 2.0 0.8 0.8 0.8 1.1 
 Relebactam 32 mg/L 2.4 1.2 0.8 0.7 1.0 
C. freundii LN10083 Cefoxitin 1 mg/L 0.8 10 11 7.8 2.25 
 Cefoxitin 4 mg/L 0.6 61 21 10 6.1 
 Cefoxitin 32 mg/L 0.6 130 30 160 260 
 Avibactam 1 mg/L 0.8 1.7 1.0 1.2 0.5 
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 Avibactam 4 mg/L 1.0 0.9 1.0 1.1 0.9 
 Avibactam 32 mg/L 0.8 1.4 1.3 0.7 0.5 
 Relebactam 1 mg/L 1.1 1.1 0.6 0.4 1.6 
 Relebactam 4 mg/L 1.2 1.4 0.7 0.5 1.8 
 Relebactam 32 mg/L 1.1 1.4 0.8 0.4 1.9 
C. freundii SE02016 Cefoxitin 1 mg/L 0.7 7.8 12 9.1 1.9 
 Cefoxitin 4 mg/L 0.6 54 19 6.5 1.6 
 Cefoxitin 32 mg/L 0.6 150 81 140 140 
 Avibactam 1 mg/L 1.1 0.5 0.7 0.8 1.0 
 Avibactam 4 mg/L 1.0 0.4 1.3 0.5 1.0 
 Avibactam 32 mg/L 0.9 0.8 0.8 0.7 1.0 
 Relebactam 1 mg/L 1.2 1.3 0.9 0.6 0.8 
 Relebactam 4 mg/L 0.9 1.8 1.1 0.4 0.6 
 Relebactam 32 mg/L 1.0 1.5 1.1 0.6 0.7 
C. freundii SE02071 Cefoxitin 1 mg/L 0.9 3.3 5.1 1.4 0.9 
 Cefoxitin 4 mg/L 0.5 27 26 4.9 6.7 
 Cefoxitin 32 mg/L 0.8 70 47 75 59 
 Avibactam 1 mg/L 1.0 1.0 1.0 1.0 1.0 
 Avibactam 4 mg/L 1.0 1.0 1.0 1.0 1.0 
 Avibactam 32 mg/L 1.0 1.0 1.0 1.0 1.0 
 Relebactam 1 mg/L 1.3 1.2 1.0 0.6 1.0 
 Relebactam 4 mg/L 1.4 1.1 1.0 0.5 1.1 
 Relebactam 32 mg/L 1.7 1.2 1.3 0.6 0.9 
P. aeruginosa H111840682 Cefoxitin 1 mg/L 0.7 2.9 29 2.1 0.7 
 Cefoxitin 4 mg/L 0.1 460 800 3.8 0.5 
 Cefoxitin 32 mg/L 0.25 2700 780 23 9.2 
 Avibactam 1 mg/L 0.3 2.2 0.8 0.0 0.0 
 Avibactam 4 mg/L 0.3 0.7 0.5 0.7 0.1 
 Avibactam 32 mg/L 0.2 170 860 182 19 
 Relebactam 1 mg/L 0.3 0.5 1.4 0.3 0.6 
 Relebactam 4 mg/L 0.8 1.6 2.8 1.0 0.3 
 Relebactam 32 mg/L 0.3 1.6 1.4 1.5 0.7 
P. aeruginosa H112220257 Cefoxitin 1 mg/L 3.8 3500 39 1.6 2.1 
 Cefoxitin 4 mg/L 2.3 33 4.0 1.2 3.6 
 Cefoxitin 32 mg/L 0.8 250 13 0.6 9.5 
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 Avibactam 1 mg/L 13 0.7 6.7 0.7 4.4 
 Avibactam 4 mg/L 3.7 0.6 8.1 1.0 9.1 
 Avibactam 32 mg/L 5.2 9.8 110 1.7 40 
 Relebactam 1 mg/L 0.9 1.3 0.5 0.2 0.4 
 Relebactam 4 mg/L 0.4 0.9 0.5 1.2 0.3 
 Relebactam 32 mg/L 1.6 1.7 4.1 3.5 7.4 
P. aeruginosa H114900202 Cefoxitin 1 mg/L 1.2 84 5 1.3 0.8 
 Cefoxitin 4 mg/L 4.1 84 12 0.7 1.4 
 Cefoxitin 32 mg/L 2.1 14000 250 1.3 5.8 
 Avibactam 1 mg/L 0.7 0.5 5.8 0.1 0.2 
 Avibactam 4 mg/L 0.7 0.2 6.6 1.0 0.2 
 Avibactam 32 mg/L 0.7 1.1 0.7 1.9 21 
 Relebactam 1 mg/L 0.9 0.7 2.1 3.7 14 
 Relebactam 4 mg/L 1.0 1.0 0.9 0.1 1.0 
 Relebactam 32 mg/L 0.9 0.8 4.1 0.5 1.6 
P. aeruginosa H114980582 Cefoxitin 1 mg/L 3.1 53 4.9 3.0 3.35 
 Cefoxitin 4 mg/L 1.9 43 33 11 170 
 Cefoxitin 32 mg/L 2.6 8500 160 24 680 
 Avibactam 1 mg/L 0.9 2.5 0.1 0.5 4.3 
 Avibactam 4 mg/L 1.0 6.8 0.4 2.3 40.7 
 Avibactam 32 mg/L 0.5 6.2 29.7 22000 1000 
 Relebactam 1 mg/L 2.3 1.3 3.1 0.8 0.8 
 Relebactam 4 mg/L 0.7 0.7 2.9 1.1 0.8 
 Relebactam 32 mg/L 0.7 1.7 1.3 2.3 0.6 
P. aeruginosa H115280631 Cefoxitin 1 mg/L 0.4 0.9 1.2 0.5 0.5 
 Cefoxitin 4 mg/L 0.9 0.7 7.1 1.25 0.3 
 Cefoxitin 32 mg/L 0.3 41 36 13 0.8 
 Avibactam 1 mg/L 0.1 0.0 0.7 0.0 3.5 
 Avibactam 4 mg/L 0.0 0.1 0.2 0.4 1.3 
 Avibactam 32 mg/L 0.1 0.0 8.0 0.1 1.1 
 Relebactam 1 mg/L 0.8 0.9 1.3 1.0 0.1 
 Relebactam 4 mg/L 4.9 0.8 1.4 0.9 1.8 
 Relebactam 32 mg/L 1.0 0.9 1.4 1.0 0.1 
 281 
Results for DBOs are averages of three technical replicates; those for cefoxitin are averages 282 
of two sets of three technical replicates, once as a control for each DBO, except: 283 
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 284 
a where one set of three replicates was excluded owing to test failure  285 
b test failure 286 
